We provide you with 20 years of free, institutional-grade data for KRBP stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KRBP. Explore the full financial landscape of KRBP stock.
| Reported Date | CIK | Ticker | Type |
|---|
Kiromic BioPharma, Inc(NASDAQ:KRBP) 
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an a...
Website: http://www.kiromic.com
Founded: 2006
Full Time Employees: 11
CEO: Maurizio Chiriva-Internati
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about KRBP stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.